Genetic testing in hereditary non-polyposis colorectal cancer families with a MSH2, MLH1, or MSH6 mutation

Autor: Hans F. A. Vasen, J. T. Wijnen, C. Tops, Anja Wagner, Aad Tibben, J. G. M. Klijn, C. A. Van Der Meer, Martinus F. Niermeijer, K Zwinderman, Hanne Meijers-Heijboer, M Kets

Publikováno v: Journal of medical genetics, 39(11), 833-837. BMJ Publishing Group
Journal of Medical Genetics, 39, 833-837. BMJ Publishing Group
Journal of Medical Genetics, 39, 833-7
Journal of Medical Genetics, 39, 11, pp. 833-7

About 5% of colorectal cancers are associated with the autosomal dominantly inherited cancer susceptibility syndrome hereditary non-polyposis colorectal cancer (HNPCC).1,2 HNPCC is characterised by a high risk of developing colorectal cancer and endo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69001ce53af807830d45137c93cd4baa
https://doi.org/10.1136/jmg.39.11.833

Screening for BRCA2 mutations in 81 Dutch breast–ovarian cancer families

Autor: Cees J. Cornelisse, Hanne Meijers-Heijboer, G.J.B. van Ommen, J. G. M. Klijn, Hans F. A. Vasen, Anne Bosch, Michael R. Stratton, T. Peelen, M. van Vliet, G. Bignell, Peter Devilee

Publikováno v: British journal of cancer, 82(1), 151-156. Nature Publishing Group
British Journal of Cancer

We have analysed 81 families with a history of breast and/or ovarian cancer for the presence of germline mutations in BRCA2 with a number of different mutation screening techniques. The protein truncation test (PTT) for exons 10 and 11 detected four

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7df08fa9608e619b7ad3c341b39185a5
https://doi.org/10.1054/bjoc.1999.0892

Infrequent CDKN2 (MTS1/p16) gene alterations in human primary breast cancer

Autor: J. G. M. Klijn, Nelleke A. Gruis, I. L. Van Staveren, John A. Foekens, Marcel Smid, Emjj Berns

Publikováno v: British Journal of Cancer

Changes which lead to excessive cyclin production or to loss of cell cycle inhibition by proteins such as p16/MTS1 may release breast tumour cells from the constraints of cell division. In order to establish the frequency of MTS1/p16 gene alteration

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b92743d32616659abd5d578e1c0e0ffb
https://doi.org/10.1038/bjc.1995.442

Pre-clinical and clinical treatment of breast cancer with antiprogestins

Autor: John A. Foekens, Steven W. J. Lamberts, H.J. Sander, B. Setyono-Han, J. G. M. Klijn, G.H. Deckers, F. H. De Jong

Publikováno v: Human Reproduction. 9:181-189

Antiprogestins form a new potential treatment modality for breast cancer and their mode of action has been assessed in vitro on several breast cancer cell lines, in vivo in rats with dimethylbenzanthracene (DMBA)-induced mammary tumours and in vivo i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a829fad94d5edce8941796369e0a25ae
https://doi.org/10.1093/humrep/9.suppl_1.181

[The value of gene expression profiles using micoarrays for the individualisation of adjuvant therapy after surgery for breast cancer]

Autor: J G M, Klijn, E G E, de Vries

Publikováno v: Nederlands tijdschrift voor geneeskunde. 149(12)

Gene-expression profiles are a promising development in determining the prognosis of patients with primary breast cancer. They accurately assess the risk on distant recurrence of disease and show if the patient might benefit from adjuvant therapy aft

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::1495c53ce20b54a5e51ae5268b032bfd
https://pubmed.ncbi.nlm.nih.gov/15813429